PT-141 Injection Dosage: What the Label and Research Say

PT-141 injection dosage for the only FDA-approved use is 1.75 mg injected subcutaneously, at least 45 minutes before anticipated sexual activity. The label allows one dose every 24 hours and no more than eight doses per month. Off-label doses used for men generally fall between 1 mg and 2 mg, but no regulatory agency has approved that range.

PT-141 is the research name for bremelanotide, a melanocortin receptor agonist sold under the brand name Vyleesi. In the United States it is approved only for premenopausal women diagnosed with hypoactive sexual desire disorder, or HSDD. That narrow approval is the reason most dosing questions have one official answer and several unofficial ones.

What the FDA Label Says About PT-141 Injection Dosage

The Vyleesi label is unusually specific, which makes it the clearest starting point for any pt-141 injection dose question.

• Dose: 1.75 mg injected subcutaneously into the abdomen or thigh.
• Timing: at least 45 minutes before anticipated sexual activity.
• Frequency: no more than one dose in 24 hours and no more than eight doses per month.
• Site rotation: rotate the injection site to reduce irritation.
• No titration: the label does not call for a low starting dose that is slowly increased.

PT-141 is not approved for use in men in the United States, and it is not approved as a general sexual enhancement drug for people without HSDD.

How Much PT-141 to Inject Off-Label

Off-label use is common, and anecdotal reports online often describe doses above the approved amount. Reported male doses cluster around 1 mg to 2 mg, with a smaller number of users describing 2.5 mg.

Higher doses do not appear to produce proportionally stronger effects. They mostly increase nausea, flushing, and blood pressure changes. Anyone comparing pt 141 dosage for men reports from forums should treat those numbers as anecdotes rather than clinical guidance.

A clinician may also weigh body size, cardiovascular history, and concurrent medications when setting a peptide pt 141 dosage for an individual patient. That individual assessment matters more than any number copied from a message board.

PT-141 Injection Dosage for Women

Women have the only FDA-approved dose: 1.75 mg subcutaneously. The clinical trials that supported approval used that fixed dose, and it is the number that appears on the label.

Some prescribers discuss starting lower for tolerability, and Reddit threads about pt-141 dosage for women often mention 0.5 mg to 1 mg starting points. Those are off-label practices, not approved alternatives. The approved product ships as a single-use autoinjector, so splitting a dose is difficult and is not part of the label.

Nausea is the most common reason women stop PT-141. Taking the injection on an empty stomach does not reliably prevent it, and the label does not recommend food restrictions.

Timing, Technique, and What Changes the Dose

PT-141 reaches peak blood levels roughly one hour after injection, and effects may last several hours. Injecting too close to sexual activity is one of the most common reasons people report that the drug did not seem to work.

Practical points to keep in mind:

1. Inject subcutaneously into the abdomen or thigh, avoiding the navel area.
2. Wait at least 45 minutes before anticipated activity.
3. Do not inject a second dose if the first one seems weak.
4. Keep a log of dose, timing, and side effects to share with a clinician.

Blood pressure can rise after a dose, so the label advises against use in people with uncontrolled hypertension or known cardiovascular disease. That restriction applies at every dose, not just at high ones.

PT-141 Injection vs Nasal Spray Dosage

Injection is the only route with an approved dose. Compounded nasal sprays are sold online, but they are not FDA-approved and absorption varies widely between products.

The difference matters when weighing pt-141 nasal spray vs injection, because a milligram of one route is not equivalent to a milligram of the other. Anyone researching pt 141 nasal spray dosage should know that compounded products are not reviewed for purity or strength.

Side Effects and Safety Considerations

Nausea is reported by a large share of users and is the most frequent reason for discontinuation. Flushing, headache, and injection-site reactions are also common.

Less common but more serious concerns include transient blood pressure increases and darkening of the gums, skin, or nails with frequent use. Focal hyperpigmentation appears to be dose- and duration-dependent, which is one reason the label caps monthly dosing.

PT-141 is not a hormone and does not raise testosterone. It is also not a treatment for erectile dysfunction, and it does not replace evaluation by a clinician when sexual problems have an underlying medical cause. Anyone with heart disease, uncontrolled blood pressure, or a history of melanoma should talk with a healthcare professional before considering PT-141 at any dose.

Key Takeaways on PT-141 Injection Dosage

• The only FDA-approved PT-141 injection dosage is 1.75 mg subcutaneously, once per 24 hours, up to eight times per month.
• Off-label male doses of 1 mg to 2 mg are widely discussed online but are not approved.
• PT-141 is not approved for men, for bodybuilding, or for general sexual enhancement.
• More PT-141 is not better; higher doses mainly add nausea and blood pressure effects.
• Compounded nasal sprays and research-grade peptides are not interchangeable with FDA-approved Vyleesi.